With Sickle Cell Results For Pyrukynd, Agios Enters Increasingly Competitive Market

 
• By Alaric DeArment

The company has significantly built up its pipeline since divesting its oncology business to Servier, with multiple Phase III readouts for Pyrukynd expected in 2024-2025.

Agios announced topline Phase II results from RISE UP • Source: Shutterstock

More from Clinical Trials

More from R&D